Drugs / phosphate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03771105 | Jan 2019 → Apr 2028 expected | X-linked hypophosphatemic rickets, hereditary hypophosphatemic rickets with hypercalciuria, hypophosphatemia, idiopathic hypercalciuria | Yale University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02016235 | Sep 2014 → Jan 2019 | Dent disease | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | phosphate | “Adult DD1 patients and control participants completed an oral phosphate supplementation intervention (1 g/d×14 days) with reassessment immediately after intervention.” PMID 41758568 ↗ Feb 2026 |
| Route | Oral | “Adult DD1 patients and control participants completed an oral phosphate supplementation intervention (1 g/d×14 days) with reassessment immediately after intervention.” PMID 41758568 ↗ Feb 2026 |